In various cancers, IGF2BP3 recognizes m6A modifications on a set of key oncogenic transcripts (such as MYC, SOX2, EGFR, etc.), forming an “m6A–IGF2BP3–oncogene” axis that drives tumorigenesis and progression, underscoring its role as a key effector protein linking m6A modification to cancer phenotypes (Zhan et al., 2023; Zhang et al., 2022; Liu et al., 2023). This evidence concerns the gene MYC and cancer.